Center for Oncology Hematology Outcomes Research and Training, Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California.
Center for Oncology Hematology Outcomes Research and Training, Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California.
Transplant Cell Ther. 2022 Dec;28(12):859.e1-859.e10. doi: 10.1016/j.jtct.2022.09.016. Epub 2022 Sep 27.
Advances in hematopoietic cell transplantation (HCT) have substantially improved patient survival, increasing the importance of studying outcomes and long-term adverse effects in the rapidly growing population of HCT survivors. Large-scale registry data from the Center for International Blood and Marrow Transplant Research (CIBMTR) are a valuable resource for studying mortality and late effects after HCT, providing detailed data reported by HCT centers on transplantation-related factors and key outcomes. This study was conducted to evaluate the robustness of CIBMTR outcome data and assess health-related outcomes and healthcare utilization among HCT recipients. We linked data from the CIBMTR for California residents with data from the population-based California Cancer Registry (CCR) and hospitalization information from the California Patient Discharge Database (PDD). In this retrospective cohort study, probabilistic and deterministic record linkage used key patient identifiers, such as Social Security number, ZIP code, sex, birth date, hematologic malignancy type and diagnosis date, and HCT type and date. Among 22,733 patients registered with the CIBMTR who underwent autologous or allogeneic HCT for hematologic malignancy between 1991 and 2016, 89.0% were matched to the CCR and/or PDD (n = 17,707 [77.9%] for both, n = 1179 [5.2%] for the CCR only, and n = 1342 [5.9%] for the PDD only). Unmatched patients were slightly more likely to have undergone a first autologous HCT than an allogeneic HCT (12.6% versus 9.0%), to have a larger number of missing linkage identifiers, and to have undergone HCT prior to 2010. Among the patients reported to the CIBMTR who matched to the CCR, 85.7% demonstrated concordance of both hematologic malignancy type and diagnosis date across data sources. This linkage presents unparalleled opportunities to advance our understanding of HCT practices and patient outcomes.
造血细胞移植（HCT）的进展大大提高了患者的生存率，因此研究 HCT 幸存者数量不断增加的情况下的结局和长期不良影响变得越来越重要。来自国际血液和骨髓移植研究中心（CIBMTR）的大型登记数据是研究 HCT 后死亡率和晚期效应的宝贵资源，提供了 HCT 中心报告的与移植相关因素和关键结局相关的详细数据。本研究旨在评估 CIBMTR 结局数据的稳健性，并评估 HCT 受者的健康相关结局和医疗保健利用情况。我们将加利福尼亚居民的 CIBMTR 数据与基于人群的加利福尼亚癌症登记处（CCR）的数据以及加利福尼亚患者出院数据库（PDD）的住院信息进行了链接。在这项回顾性队列研究中，使用了关键的患者标识符（如社会安全号码、ZIP 码、性别、出生日期、血液恶性肿瘤类型和诊断日期以及 HCT 类型和日期）进行概率和确定性记录链接。在 1991 年至 2016 年间，在 CIBMTR 登记接受自体或同种异体 HCT 治疗血液恶性肿瘤的 22733 名患者中，有 89.0%与 CCR 和/或 PDD 相匹配（n=17707 [77.9%]，同时与 CCR 相匹配，n=1179 [5.2%]仅与 CCR 相匹配，n=1342 [5.9%]仅与 PDD 相匹配）。未匹配的患者更有可能接受首次自体 HCT 而非同种异体 HCT（12.6%比 9.0%），具有更多缺失的链接标识符，并且更有可能在 2010 年前接受 HCT。在向 CIBMTR 报告并与 CCR 相匹配的患者中，85.7%的患者在两种数据源中血液恶性肿瘤类型和诊断日期都具有一致性。这种链接为我们深入了解 HCT 实践和患者结局提供了无与伦比的机会。
